(Q44303475)

1 December 2017

0 references

The clinical practice impact of the Women's Health Initiative: political vs biologic correctness (English)

1 reference

1 December 2017

Morris Notelovitz

1

1 reference

1 December 2017

publication date

1 January 2003

1 reference

1 December 2017

1 reference

1 December 2017

volume

44

1 reference

1 December 2017

issue

1

1 reference

1 December 2017

page(s)

3-9

1 reference

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900333-X

7 January 2021

Hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900333-X

7 January 2021

Production and actions of estrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900333-X

7 January 2021

Estrogen and the risk of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900333-X

7 January 2021

Serum estradiol level and risk of breast cancer during treatment with raloxifene

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900333-X

7 January 2021

Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900333-X

7 January 2021

Hormone therapy and the cardiovascular system

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900333-X

7 January 2021

Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900333-X

7 January 2021

Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900333-X

7 January 2021

Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900333-X

7 January 2021

Is BMU-coupling a strain-regulated phenomenon? A finite element analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900333-X

7 January 2021

Estrogen therapy and osteoporosis: principles & practice

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900333-X

7 January 2021

Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900333-X

7 January 2021

Treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900333-X

7 January 2021

Serum Estradiol-Binding Profiles in Postmenopausal Women Undergoing Three Common Estrogen Replacement Therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900333-X

7 January 2021

Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900333-X

7 January 2021

Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900333-X

7 January 2021

Effect of medroxyprogesterone acetate and norethisterone on serum-stimulated and estradiol-inhibited proliferation of human coronary artery smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900333-X

7 January 2021

Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression: role of the glucocorticoid receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900333-X

7 January 2021

Dydrogesterone does not reverse the effects of estradiol on endothelium-dependant vasodilation in postmenopausal women: a randomised clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900333-X

7 January 2021

10.1016/S0378-5122(02)00333-X

Identifiers

DOI

1 reference

1 December 2017

1 reference